GlassScriptPhysician profile
Balraj Kaur
NPI 1679123871
$3,261.06
in general payments reported to CMS, 2019-2025
20 companies · $800 in 2025
The $800 reported for 2025 was more than what 84% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $631 · 2022: $443 · 2023: $552 · 2024: $836 · 2025: $800.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,188.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,187.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $904.46 | 2021-2025 | Lifevest |
| Abiomed | $481.03 | 2022-2025 | Impella |
| Kestra Medical Technology Services, INC. | $378.24 | 2025 | Assure Wcd |
| Pfizer INC. | $272.82 | 2021-2023 | |
| Novartis Pharmaceuticals Corporation | $234.76 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $183.17 | 2021-2025 | Farxiga |
| Heartflow, INC. | $146.01 | 2024 | |
| Alnylam Pharmaceuticals INC. | $144.23 | 2021-2025 | Onpattro, Amvuttra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $98.02 | 2021-2025 | Jardiance |
| Kiniksa Pharmaceuticals, LTD. | $70.82 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $65.94 | 2023-2024 | Livtencity |
| Scpharmaceuticals INC. | $59.80 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $54.47 | 2022-2024 | Verquvo |
| Medtronic, INC. | $37.63 | 2023 | Linq II |
| Bridgebio Pharma, INC. | $32.13 | 2025 | Attruby |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $28.39 | 2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Novo Nordisk INC | $24.28 | 2025 | Ozempic |
| Esperion Therapeutics, INC. | $21.28 | 2021 | |
| Lexicon Pharmaceuticals, INC. | $18.20 | 2023 | Inpefa |
| Biosense Webster, INC. | $5.38 | 2024 | Carto 3 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Balraj Kaur listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.